MX375113B - Anticuerpos que se unen específicamente a la toxina alfa de staphylococcus aureus y métodos de uso. - Google Patents

Anticuerpos que se unen específicamente a la toxina alfa de staphylococcus aureus y métodos de uso.

Info

Publication number
MX375113B
MX375113B MX2017001101A MX2017001101A MX375113B MX 375113 B MX375113 B MX 375113B MX 2017001101 A MX2017001101 A MX 2017001101A MX 2017001101 A MX2017001101 A MX 2017001101A MX 375113 B MX375113 B MX 375113B
Authority
MX
Mexico
Prior art keywords
antibodies
methods
staphylococcus aureus
alpha toxin
specifically bind
Prior art date
Application number
MX2017001101A
Other languages
English (en)
Inventor
Bret Sellman
Christine Tkaczyk
Jamese Johnson Hilliard
Lei Hua
Li Peng
Melissa Damschroder
Partha Chowdhury
Reena Varkey
Vaheh Oganesyan
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46639171&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX375113(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MX375113B publication Critical patent/MX375113B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/44—Multiple drug resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/709—Toxin induced
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)

Abstract

La descripción proporciona composiciones, métodos y fabricación y métodos de uso de anticuerpos y fragmentos que unen la toxina alfa estafilococo aureus. Más específicamente, la descripción proporciona las secuencias de la región VH CDR y VL CDR de anticuerpos o fragmentos que se unen al antígeno. También se describen los métodos de prevenir, tratar o manejar una condición asociada con la infección de estafilococo aureus que utiliza los anticuerpos.
MX2017001101A 2011-02-08 2012-02-07 Anticuerpos que se unen específicamente a la toxina alfa de staphylococcus aureus y métodos de uso. MX375113B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161440581P 2011-02-08 2011-02-08
PCT/US2012/024201 WO2012109285A2 (en) 2011-02-08 2012-02-07 Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use

Publications (1)

Publication Number Publication Date
MX375113B true MX375113B (es) 2025-03-04

Family

ID=46639171

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2013009127A MX345285B (es) 2011-02-08 2012-02-07 Anticuerpos que se unen especificamente a la toxina alfa de staphylococcus aureus y metodos de uso.
MX2017001101A MX375113B (es) 2011-02-08 2012-02-07 Anticuerpos que se unen específicamente a la toxina alfa de staphylococcus aureus y métodos de uso.
MX2020009700A MX2020009700A (es) 2011-02-08 2013-08-07 Anticuerpos que se unen especificamente a la toxina alfa de staphylococcus aureus y metodos de uso.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013009127A MX345285B (es) 2011-02-08 2012-02-07 Anticuerpos que se unen especificamente a la toxina alfa de staphylococcus aureus y metodos de uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020009700A MX2020009700A (es) 2011-02-08 2013-08-07 Anticuerpos que se unen especificamente a la toxina alfa de staphylococcus aureus y metodos de uso.

Country Status (24)

Country Link
US (1) US9527905B2 (es)
EP (2) EP3470526A3 (es)
JP (4) JP2014508748A (es)
KR (1) KR101993839B1 (es)
CN (2) CN103443285B9 (es)
AU (1) AU2012214531C1 (es)
BR (1) BR112013020086B1 (es)
CA (1) CA2826566C (es)
CY (1) CY1121389T1 (es)
DK (1) DK2673373T6 (es)
ES (1) ES2709065T7 (es)
HR (1) HRP20182017T4 (es)
HU (1) HUE040734T2 (es)
LT (1) LT2673373T (es)
MX (3) MX345285B (es)
PL (1) PL2673373T6 (es)
PT (1) PT2673373T (es)
RS (1) RS58190B2 (es)
RU (1) RU2620065C2 (es)
SG (3) SG10201913690SA (es)
SI (1) SI2673373T1 (es)
SM (1) SMT201800635T1 (es)
TR (1) TR201817932T4 (es)
WO (1) WO2012109285A2 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013031485B1 (pt) 2011-06-10 2022-06-14 Medimmune, Llc Anticorpo monoclonal isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, usos e método in vitro para bloqueio ou prevenção da ligação de p. aeruginosa a células epiteliais
BR112014011028B1 (pt) 2011-11-07 2021-03-02 Medimmune, Llc anticorpo biespecífico, composição, e, uso da composição
WO2013096948A1 (en) 2011-12-23 2013-06-27 Lydon Nicholas B Immunoglobulins and variants directed against pathogenic microbes
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
JP2015535005A (ja) * 2012-11-06 2015-12-07 メディミューン，エルエルシー 抗シュードモナス属（Ｐｓｅｕｄｏｍｏｎａｓ）ＰｓｌおよびＰｃｒＶ結合分子を用いた併用治療
MX375324B (es) * 2012-11-06 2025-03-06 Medimmune Llc Anticuerpos contra determinantes de la superficie de s. aureus.
US9845348B2 (en) * 2012-11-06 2017-12-19 Medimmune, Llc Methods of treating S. aureus-associated diseases
EP3057989A1 (en) * 2013-10-17 2016-08-24 ARSANIS Biosciences GmbH Cross-reactive staphylococcus aureus antibody sequences
JP2017504325A (ja) * 2014-01-14 2017-02-09 インテグレイテッド バイオセラピューティクス，インコーポレイテッド バクテリオシンの細胞壁ターゲティングドメインを用いた細菌感染部位への免疫学的機能のターゲティング方法
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
TWI719938B (zh) * 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
AU2015303147A1 (en) * 2014-08-12 2017-02-23 Arsanis Biosciences Gmbh Predicting S. aureus disease
RS60739B1 (sr) 2014-11-17 2020-09-30 Regeneron Pharma Postupci za lečenje tumora upotrebom cd3xcd20 bispecifičnog antitela
JP6889701B2 (ja) 2015-09-24 2021-06-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ アルファ溶血素バリアント
US20190077851A1 (en) * 2015-10-30 2019-03-14 Bruno Francois Methods of using anti-alpha toxin antibody
TW202311284A (zh) * 2017-01-03 2023-03-16 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
EP3580239A4 (en) 2017-02-09 2021-07-28 Bluefin Biomedicine, Inc. ANTIBODY ANTI-ILT3 AND ANTIBODY-DRUG CONJUGATES
CN108456250B (zh) * 2017-02-17 2025-11-28 恺兴生命科技(上海)有限公司 靶向il-13ra2的抗体及其应用
CN109384844B (zh) * 2017-08-04 2020-12-18 中国人民解放军军事医学科学院基础医学研究所 一种抗金黄色葡萄球菌α溶血素单克隆抗体及应用
TWI902669B (zh) 2018-07-24 2025-11-01 美商麥迪紐有限責任公司 抗金黃色葡萄球菌凝集因子a(clfa)之抗體
WO2020041532A1 (en) * 2018-08-21 2020-02-27 Sf17 Therapeutics, Inc. Compositions and methods for treating progressive neurodegenerative diseases
RS66543B1 (sr) 2018-08-31 2025-03-31 Regeneron Pharma Strategija doziranja koja ublažava sindrom oslobađanja citokina za cd3/cd20 bispecifična antitela
MX2021004114A (es) 2018-10-09 2021-07-16 Medimmune Llc Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus.
CN113164602A (zh) 2018-10-09 2021-07-23 免疫医疗有限责任公司 抗金黄色葡萄球菌抗体的组合
CN113811544A (zh) * 2019-03-13 2021-12-17 免疫医疗有限责任公司 减少定殖患者中的金黄色葡萄球菌感染
WO2020210650A1 (en) 2019-04-12 2020-10-15 Medimmune, Llc Neutralization of tgf-beta or alpha-v-beta-8 integrin for s. aureus infections
CN112538112B (zh) * 2019-09-20 2023-10-27 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其应用
CN113444172A (zh) * 2020-03-25 2021-09-28 兴盟生物医药(苏州)有限公司 金黄色葡萄球菌α-毒素特异性抗体及其应用
JP2024503425A (ja) * 2021-01-11 2024-01-25 星濟生物（蘇州）有限公司 黄色ブドウ球菌のα毒素を標的とした抗原結合たんぱく質およびその応用
CN112941136B (zh) * 2021-03-24 2023-04-28 成都欧林生物科技股份有限公司 一种重组金黄色葡萄球菌疫苗hi抗原蛋白的纯化方法
CN114455048B (zh) * 2022-03-02 2023-03-14 江苏微导纳米科技股份有限公司 一种桨杆
WO2023208123A1 (zh) * 2022-04-28 2023-11-02 珠海泰诺麦博制药股份有限公司 特异性结合金黄色葡萄球菌Hla毒素的全人源单克隆抗体
CN116589566A (zh) * 2022-11-18 2023-08-15 昆明医科大学第一附属医院 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用
CN116023486B (zh) * 2023-01-10 2024-10-08 西北农林科技大学 金黄色葡萄球菌α-溶血素纳米抗体、制备方法及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DE69737513T2 (de) 1996-04-25 2007-12-13 Genicon Sciences Corp., San Diego Teilchenförmiges markierungsmittel verwendendes analytassay
EP2322644A1 (en) 2000-06-28 2011-05-18 GlycoFi, Inc. Methods for producing modified glycoproteins
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
EP1479695B1 (en) 2003-05-14 2010-02-17 Kenta Biotech AG Human monoclonal antibody specific for lipopolysaccharides (LPS) of serotype IATS O6 of Pseudomonas aeruginosa
CN1324049C (zh) 2003-08-04 2007-07-04 中国疾病预防控制中心病毒病预防控制所 人源抗sars冠状病毒基因工程抗体
KR100891620B1 (ko) 2004-04-13 2009-04-02 에프. 호프만-라 로슈 아게 항-ｐ-셀렉틴 항체
KR20070058631A (ko) * 2004-09-22 2007-06-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
BRPI0707290A2 (pt) 2006-01-17 2011-08-16 Biolex Therapeutics Inc composições e métodos para humanização e otimização de n-glicanas em plantas
TW200813091A (en) * 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
EP2043690A1 (en) * 2006-06-12 2009-04-08 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
BRPI0811193A2 (pt) * 2007-05-31 2014-11-11 Merck & Co Inc Proteína de ligação a antígeno isolada, ácido nucleico, célula recombinante, métodos para produzir uma proteína e para proteger ou tratar contra uma infecção por s. aureus em paciente, composição farmacêutica, uso da proteína de ligação a antígeno, e, polipeptídeo.
ES2650224T3 (es) 2007-08-21 2018-01-17 Amgen, Inc. Proteínas de unión al antígeno C-FMS humano
EP2185190B1 (en) * 2007-08-31 2015-06-24 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
US8172115B1 (en) 2008-04-10 2012-05-08 Spencer Forrest, Inc. Hair building solids dispenser for one handed operation
CN102171247A (zh) * 2008-07-02 2011-08-31 特鲁比昂药品公司 TNF-α拮抗剂多靶点结合蛋白
EP2208787A1 (en) * 2009-01-19 2010-07-21 Université de Liège A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
GB2467939A (en) * 2009-02-20 2010-08-25 Univ Sheffield Removal of bacteria from media
HUE036372T2 (hu) * 2009-06-22 2018-07-30 Wyeth Llc Staphylococcus aureus antigének immunogén készítményei
MX375324B (es) * 2012-11-06 2025-03-06 Medimmune Llc Anticuerpos contra determinantes de la superficie de s. aureus.

Also Published As

Publication number Publication date
BR112013020086A2 (pt) 2016-11-22
HRP20182017T4 (hr) 2021-08-20
SG10201913690SA (en) 2020-03-30
CN103443285A (zh) 2013-12-11
AU2012214531B2 (en) 2017-03-16
EP2673373A4 (en) 2015-06-17
RS58190B1 (sr) 2019-03-29
MX345285B (es) 2017-01-24
WO2012109285A3 (en) 2012-10-04
CN103443285B (zh) 2017-06-23
CN107474133B (zh) 2021-10-15
DK2673373T6 (da) 2021-08-23
JP2020172489A (ja) 2020-10-22
SG192212A1 (en) 2013-09-30
TR201817932T4 (en) 2019-02-21
LT2673373T (lt) 2019-01-25
EP2673373B3 (en) 2021-06-02
ES2709065T3 (es) 2019-04-15
ES2709065T7 (es) 2021-12-09
JP2014508748A (ja) 2014-04-10
RS58190B2 (sr) 2021-08-31
RU2013141134A (ru) 2015-03-20
EP2673373A2 (en) 2013-12-18
JP7047017B2 (ja) 2022-04-04
SG10201600899PA (en) 2016-03-30
HRP20182017T1 (hr) 2019-02-08
EP3470526A2 (en) 2019-04-17
HUE040734T2 (hu) 2019-03-28
CA2826566A1 (en) 2012-08-16
EP2673373B1 (en) 2018-08-29
US9527905B2 (en) 2016-12-27
PT2673373T (pt) 2018-12-05
JP2019011329A (ja) 2019-01-24
CY1121389T1 (el) 2020-05-29
HK1248257A1 (zh) 2018-10-12
RU2620065C2 (ru) 2017-05-22
SMT201800635T1 (it) 2019-01-11
PL2673373T6 (pl) 2021-09-27
MX2013009127A (es) 2014-01-31
AU2012214531C1 (en) 2021-07-29
JP2017128575A (ja) 2017-07-27
EP3470526A3 (en) 2019-07-17
SI2673373T1 (sl) 2019-03-29
BR112013020086B1 (pt) 2020-12-08
MX2020009700A (es) 2020-10-07
KR20140019344A (ko) 2014-02-14
DK2673373T3 (da) 2019-01-02
WO2012109285A2 (en) 2012-08-16
PL2673373T3 (pl) 2019-04-30
JP6367393B2 (ja) 2018-08-01
US20140072577A1 (en) 2014-03-13
KR101993839B1 (ko) 2019-06-28
JP6723293B2 (ja) 2020-07-15
CN103443285B9 (zh) 2018-04-24
CA2826566C (en) 2022-09-13
CN107474133A (zh) 2017-12-15

Similar Documents

Publication Publication Date Title
MX375113B (es) Anticuerpos que se unen específicamente a la toxina alfa de staphylococcus aureus y métodos de uso.
CY1122278T1 (el) Αντι il-36r αντισωματα
CY1123145T1 (el) Anti-cd40 αντισωματα
CL2018001000A1 (es) Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr.
MX373245B (es) Anticuerpos cd3 humanizados o quiméricos.
EA201500995A1 (ru) Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения
MX2017000985A (es) Anticuerpos anti-pd-1.
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
PH12016502372A1 (en) Compositions and methods for treating and preventing staphylococcus aureus infections
MX2015005477A (es) Anticuerpos contra determinantes de la superficie de s. aureus.
EA201791270A1 (ru) Модифицированные april-связывающие антитела
MX370597B (es) Uso de un anticuerpo biespecífico para dll3 y cd3 en el tratamiento y profilaxis de cáncer.
EA201490850A1 (ru) Состав антитела, пригодный для профилактики и лечения амилоидоза, его варианты и способ его получения
EA201391389A1 (ru) Кристаллы антител против склеростина и составы на их основе
EA201890548A1 (ru) Антитела к il-23
MX2013009151A (es) Inmunoterapia mejorada.
EA201400345A1 (ru) АНТИТЕЛА, ОБЛАДАЮЩИЕ СПОСОБНОСТЬЮ НЕЙТРАЛИЗОВАТЬ ГЛАВНЫЕ ЭКЗОТОКСИНЫ TcdA И TcdB CLOSTRIDIUM DIFFICILE
CR20140303A (es) Composiciones y métodos para anticuerpos que actúan sobre el factor p
AR104250A1 (es) Anticuerpo anti-notch4 humano
UA113879C2 (xx) ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ
EP4079760A3 (en) Antibodies against clostridium difficile toxins and methods of using the same
MX2016007212A (es) Anticuerpos dirigidos contra la toxina lukgh (lukab) de staphylococcus aureus y secuencias de anticuerpos.
UY36262A (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
MX378452B (es) Anticuerpos monoclonales anti-+)--metanfetamina.
UY36922A (es) Inhibidores de asgr